The trial is taking place at:
P

Prolato Clinical Research Center | Houston, TX

Veeva-enabled site

Safety and Tolerability of BION-1301 in Healthy Volunteers and Adults With IgA Nephropathy (IgAN)

C

Chinook Therapeutics

Status and phase

Active, not recruiting
Phase 2
Phase 1

Conditions

IgA Nephropathy

Treatments

Drug: Placebo Multiple Doses
Drug: BION-1301 Single Dose
Drug: BION-1301 Multiple Doses
Drug: Placebo Single Dose

Study type

Interventional

Funder types

Industry

Identifiers

NCT03945318
ADU-CL-19
2018-003360-31 (EudraCT Number)

Details and patient eligibility

About

Multicenter study designed to evaluate the safety, tolerability, pharmacokinetics (PK), and pharmacodynamics (PD) of BION-1301 in healthy volunteers and adults with IgA Nephropathy (IgAN).

Full description

This is a Phase 1/2 study of BION-1301, a first-in-class humanized IgG4 anti-a proliferation-inducing ligand (APRIL) monoclonal antibody. The study will be conducted in three parts. Part 1: double-blind, randomized, placebo-controlled, single ascending dose (SAD) in healthy volunteers (HVs). Part 2: double-blind, randomized, placebo-controlled multiple ascending dose (MAD) in HVs. Part 3: Open-label, multiple dose (MD) in participants with IgAN. Part 4: Retreatment period Parts 1 and 2 have been completed. Part 3 enrollment is complete. Part 4 enrollment is open for eligible participants from Part 3. The study will enroll up to 40 participants with IgAN.

Enrollment

103 patients

Sex

All

Ages

18+ years old

Volunteers

Accepts Healthy Volunteers

Inclusion and exclusion criteria

Inclusion Criteria for Healthy Volunteers:

  • Healthy male or female volunteers, 18 to 55 years old
  • Females must be of non-childbearing potential
  • Males must agree to follow the protocol-specified contraception guidance
  • Body mass index (BMI) between 18 and 35 kg/m^2, with a weight of at least 50 kg
  • Non-smoker, defined as an individual who has not smoked previously and/or who has discontinued smoking or the use of nicotine/nicotine-containing products at least 3 months before Screening
  • Able to provide signed informed consent

Exclusion Criteria for Healthy Volunteers:

  • Regular consumption of alcohol within 6 months prior to Screening, or use of soft drugs (such as marijuana) within 3 months prior to Screening, or hard drugs (such as cocaine and phencyclidine) within 1 year prior to Screening and/or positive blood or urine test results for drugs of abuse or alcohol at Screening or Admission
  • Donated blood in the 3 months prior to the first dose of study drug, plasma in the 7 days prior to the first dose of study drug, or platelets in the 6 weeks prior to the first dose of study drug
  • History or evidence of a clinically significant disorder, condition, or disease that could pose a risk to subject safety or interfere with the study, or would make the subject unsuitable for participation, eg, respiratory, renal, hepatic, gastrointestinal, hematological, lymphatic, neurological, cardiovascular, or psychiatric disease
  • Female who is breastfeeding or who has a positive serum pregnancy test at Screening or a positive urine pregnancy test on Day -1

Inclusion Criteria for Adults with IgAN:

  • Male or female ≥18 years old at Screening
  • Women of child-bearing potential (WOCBP; per CTFG 2014) must agree to follow the protocol-specified contraception guidance throughout the study (from Screening through approximately 6 months after the final dose of study drug)
  • Males must agree to follow the protocol-specified contraception guidance throughout the study (from Screening through approximately 6 months after the final dose of study drug)
  • BMI between 18 and 40 kg/m^2, inclusive, at Screening with a weight of at least 50 kg
  • Diagnosis of IgAN verified by biopsy taken within the past 10 years
  • Urine protein ≥ 0.5 g/24h; OR UPCR ≥ 0.5 g/g (or ≥ 50 mg/mmol)
  • eGFR (per Chronic Kidney Disease Epidemiology Collaboration [CKD-EPI] formula) or measured GFR ≥ 30 mL/min per 1.73 m^2
  • Stable on an optimized dose of angiotensin converting enzyme (ACE) inhibitors and/or angiotensin-receptor blockers (ARBs) for at least 3 months prior to Screening or intolerant to ACE/ARB

Exclusion Criteria for Adults with IgAN:

  • Known or suspected allergy or hypersensitivity to any component of BION-1301, or history of severe hypersensitivity reaction to any monoclonal antibody
  • Donated blood in the 3 months prior to the first dose of study drug; plasma in the 7 days prior to the first dose of study drug; or platelets in the 6 weeks prior to the first dose of study drug
  • Participated in any other study in which receipt of an investigational new drug, or investigational device occurred within 28 days, or 5 half-lives (whichever is longer) of first dose of study drug in the present study
  • Secondary forms of IgAN as defined by the treating physician (eg, Henoch-Schönlein purpura patients and those with associated alcoholic cirrhosis)
  • Received systemic corticosteroid therapy (> 10 mg/day of prednisone or equivalent) or any other form of immunosuppressive therapy within 3 months prior to the first dose of study drug

PART 4 Eligibility Criteria for Re-treatment Due to Evidence of Disease Progression (Option 1) Inclusion Criteria for Re-treatment Due to Evidence of Disease Progression

  • Completed Part 3 of the study through Week 124 and entered the 52-week follow-up period.
  • UPCR ≥ 0.5 g/g AND ≥ 30% increase from EOT (Week 124). Both proteinuria criteria must be met by a 24-hour urine assessment during the 52-week follow-up period. In addition to the scheduled assessments, investigators may order periodic FMV assessments (for example monthly) to follow a patient more closely. Based on an off-schedule FMV result, or other laboratory or clinical evidence, investigators may order an off-schedule 24-urine collection to confirm disease progression.

Exclusion Criteria for Re-treatment Due to Evidence of Disease Progression

1. Based on the Investigator's judgment, the patient would not benefit from resuming treatment with BION-1301 or there is a safety concern for the individual patient which outweighs the expected benefit from resuming treatment.

Eligibility Criteria for Optional Re-treatment (Option 2) Inclusion Criteria for Optional Re-treatment 1. Completed Part 3 of the study through Week 124 and completed of the 52-week follow-up period.

Exclusion Criteria for Optional Re-treatment

1. Based on the Investigator's judgment, the patient would not benefit from resuming treatment with BION-1301 or there is a safety concern for the individual patient which outweighs the expected benefit from resuming treatment.

Trial design

Primary purpose

Treatment

Allocation

Randomized

Interventional model

Parallel Assignment

Masking

Triple Blind

103 participants in 6 patient groups, including a placebo group

Part 1: BION-1301
Experimental group
Description:
Up to 5 cohorts with single ascending doses of BION-1301 administered by intravenous (IV) infusion.
Treatment:
Drug: BION-1301 Single Dose
Part 1: Placebo
Placebo Comparator group
Description:
Participants will receive a single dose of placebo administered by IV infusion.
Treatment:
Drug: Placebo Single Dose
Part 2: BION-1301
Experimental group
Description:
Up to 4 cohorts with multiple doses of BION-1301 administered by intravenous (IV) infusion.
Treatment:
Drug: BION-1301 Multiple Doses
Part 2: Placebo
Placebo Comparator group
Description:
Participants will receive placebo by IV infusion.
Treatment:
Drug: Placebo Multiple Doses
Part 3: BION-1301
Experimental group
Description:
Two cohorts of participants will receive multiple doses of BION-1301 by IV infusion (Cohort 1) or SC injection (Cohort 2) at 600mg/biweekly.
Treatment:
Drug: BION-1301 Multiple Doses
Part 4 Retreatment: BION-1301
Experimental group
Description:
Eligible participants from Part 3 may enroll in Part 4 due to disease progression or by choice for optional retreatment and receive SC injection at 600mg/biweekly.
Treatment:
Drug: BION-1301 Single Dose

Trial contacts and locations

18

Loading...

Data sourced from clinicaltrials.gov

Clinical trials

Find clinical trialsTrials by location
© Copyright 2024 Veeva Systems